Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD19-CD22 CAR-T in R/R B-cell Lymphoma
NCT04715217Phase 2Recruiting
- Sponsor
- Shanxi Cancer Hospital
- Start
- Jan 2021
- Primary completion
- Oct 2024
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 2, open-label trial of KQ-2002 in B cell lymphoma (4 arms), sponsored by Shanxi Cancer Hospital. Primary endpoints: Dose Limiting Toxicity at 28 days and Objective Response Rate at 2 years. Started Jan 2021; status: recruiting.
02
Drugs
KQ-2002
03
Conditions
B cell lymphoma
Beyond the preview
Go deeper on NCT04715217.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04715217.